Table 2.
Summary of selected clinical trials targeting TAMs in pancreatic cancer.
| Class | Target | Compound/Class | Combination Partners | Phase | Sponsor | Trials ID | Status |
|---|---|---|---|---|---|---|---|
| Small molecule | CSF1R | Pexidartinib | Durvalumab (anti-PDL1) | I | AstraZeneca and Plexxikon | NCT02777710 | Complete [210] |
| ARRY-382 | Pembrolizumab (anti-PD1) | II | Pfizer | NCT02880371 | Complete [211] | ||
| CCR2 | PF-04136309 | FOLFIRINOX | I | Washington University | NCT01413022 | Complete [149] | |
| CCX872 | FOLFIRINOX | I | ChemoCentryx | NCT02345408 | Ongoing [150] | ||
| VEGFR | Cediranib | Olaparib (PARP inhibitor) | II | AstraZeneca | NCT02498613 | Ongoing, unpublished | |
| TGFβ | Galunisertib | Durvalumab (anti-PDL1) | I | AstraZeneca | NCT02734160 | Complete [212] | |
| PI3K | Buparlisib (BKM120) | FOLFOX6 | I | UNC Lineberger | NCT01571024 | Complete, unpublished | |
| LY3023414 | Gemcitabine/Capecitabine and Abemaciclib | II | Eli Lilly and Company | NCT02981342 | Complete [213] | ||
| BTK | Ibrutinib | Nab-paclitaxel and Gemcitabine | III | Pharmacyclics LLC | NCT02436668 | Complete [214] | |
| Monoclonal antibody | CSF1R | Emactuzumab (RG7155) | RG7876 (anti-CD40) | I | Hoffmann-La Roche | NCT02760797 | Complete [188] |
| AMG820 | Pembrolizumab (anti-PD1) | I | Amgen | NCT02713529 | Complete [189] | ||
| Cabiralizumab (FPA008) | Nivolumab (anti-PD1) | I | FivePrime/BMS | NCT02526017 | Complete [215] | ||
| MCS110 | PDR001 (anti-PD1) | I/II | Novartis | NCT02807844 | Complete [216] | ||
| Cabiralizumab | Nivolumab (anti-PD1) and Stereotactic Body Radiotherapy | II | NYU Langone Health | NCT03599362 | Complete [217] | ||
| Cabiralizumab | Nivolumab (anti-PD1), gemcitabine, Nab-paclitaxel | II | Bristol-Myers Squibb | NCT03336216 | Ongoing[215] | ||
| IMC-CS4 (LY3022855) | Cyclophosphamide, pembrolizumab (anti-PD1), GVAX | I | Merck Sharp & Dohme Corp.Eli Lilly and Company | NCT03153410 | Ongoing, unpublished | ||
| CD40 | CP-870,893 | Gemcitabine | I | Hoffmann-La Roche | NCT00711191 | Complete [158] | |
| RO7009789 | Nab-paclitaxel and Gemcitabine | I | Abramson Cancer Center of the University of Pennsylvania | NCT02588443 | Complete, unpublished | ||
| APX005M (Sotigalimab) | Nivolumab, Gemcitabine, Nab-Paclitaxel | I/II | Parker Institute for Cancer Immunotherapy | NCT03214250 | Ongoing[162] | ||
| SEA-CD40 | Pembrolizumab, Gemcitabine, and Nab-Paclitaxel | I | Seagen Inc. | NCT02376699 | Ongoing[218] |